Amitriptyline is a tricyclic antidepressant used for major depressive disorder and, off-label, for neuropathic pain, migraine prevention, fibromyalgia, and insomnia. It works by modulating serotonin and norepinephrine while providing antihistamine and anticholinergic effects, which explains both benefits and side effects. Typically taken at night, doses start low and are titrated to effect. This guide explains uses, dosing, precautions, side effects, interactions, and what to do if you miss a dose or overdose. It also outlines Australia prescription rules and safe, legal access through licensed clinicians, pharmacies, and telehealth. Educational only; talk with your healthcare professional for personalized, safe, effective care.
Amitriptyline is a tricyclic antidepressant (TCA) registered in Australia for major depressive disorder. Clinicians also use it off-label for persistent pain and related conditions because it can aid sleep and modulate pain pathways. Common off-label uses include neuropathic pain (for example, diabetic neuropathy and postherpetic neuralgia), migraine prevention, fibromyalgia, temporomandibular joint disorder, irritable bowel syndrome, interstitial cystitis, and tension-type headache. By inhibiting serotonin and noradrenaline reuptake and exerting antihistamine effects, it may improve sleep continuity, mood, and pain tolerance.
Onset varies by condition. For depression, mood improvements often emerge after 2–4 weeks, with full benefit sometimes taking 6–8 weeks at an effective dose. For neuropathic pain and migraine prophylaxis, some people notice benefit within 1–2 weeks once a target dose is reached, though several weeks may be needed for best effect. Sedation is common, so dosing at bedtime is typical and can help when insomnia is also present.
A gradual titration approach helps balance benefit and tolerability. For depression, prescribers often start with 25–50 mg at night or in divided doses, then increase by 25–50 mg every few days as tolerated. Usual maintenance is 75–150 mg daily; some patients may need up to 200 mg under close supervision. Older adults usually begin at 10–25 mg nightly due to greater sensitivity to anticholinergic and cardiac effects.
For neuropathic pain, migraine prevention, and other off-label uses, lower doses often suffice. A common plan begins at 10–25 mg at night, increasing by 10–25 mg every 3–7 days to a typical range of 25–75 mg nightly. Using the lowest effective dose can reduce daytime drowsiness, dry mouth, constipation, and dizziness. If sedation is problematic, reducing the dose or taking it earlier in the evening may help.
Take amitriptyline consistently, preferably at bedtime, with or without food. Do not crush or chew tablets. If you miss a dose, follow the advice below. Do not stop suddenly; taper over weeks to minimise discontinuation symptoms such as nausea, headache, sleep disturbance, irritability, and flu-like feelings. Always individualise dosing with your prescriber, particularly when switching to or from other antidepressants to avoid interactions and serotonin syndrome risk.
Amitriptyline carries a boxed warning for increased risk of suicidal thoughts and behaviours in children, adolescents, and young adults, particularly early in treatment or during dose changes. Monitor mood, behaviour, and sleep closely, and seek prompt medical care for new or worsening depression, agitation, or suicidal thinking. Older adults are more prone to confusion, falls, anticholinergic effects, and cardiac conduction issues; conservative dosing and fall-prevention strategies are recommended.
Cardiac safety is important. TCAs can prolong PR, QRS, and QT intervals. People with cardiovascular disease, arrhythmias, or electrolyte disturbances may need baseline and follow-up ECGs, especially at higher doses. Avoid dehydration and correct low potassium or magnesium to reduce arrhythmia risk. Use caution with glaucoma (particularly angle-closure), urinary retention or BPH, severe constipation, seizure disorders, thyroid disease, and liver impairment. Alcohol and other sedatives can worsen drowsiness and impair coordination. Photosensitivity can occur—use sun protection if you notice increased sensitivity.
Do not use amitriptyline if you have hypersensitivity to TCAs, have had a recent myocardial infarction, or are taking a monoamine oxidase inhibitor (MAOI) or within 14 days of MAOI use (including linezolid or IV methylene blue) due to severe interaction risk and potential hypertensive crisis. It is contraindicated during the acute recovery phase after MI and should be avoided in uncontrolled narrow-angle glaucoma and severe urinary retention. Use extreme caution—or consider alternatives—if there is a history of significant arrhythmias or prolonged QT interval.
Common effects reflect anticholinergic and antihistamine actions: dry mouth, constipation, blurred vision, urinary hesitancy, drowsiness, dizziness, increased appetite, and weight gain. Orthostatic hypotension may lead to lightheadedness or fainting on standing—rise slowly and stay hydrated. Daytime grogginess often improves with dose adjustments or earlier evening dosing. Sipping water, sugar-free gum, adding fibre, and maintaining hydration can help ease dryness and constipation.
Less common but important effects include confusion (particularly in older adults), sweating, tremor, sexual dysfunction, and photosensitivity. TCAs can affect cardiac conduction and rhythm; seek care for palpitations, fainting, chest pain, or shortness of breath. Rare but serious events include angle-closure glaucoma, significant urinary retention, seizures, severe constipation/ileus, and hepatotoxicity (watch for dark urine, jaundice, or right upper abdominal pain).
Serotonin syndrome can occur when combined with other serotonergic medicines. Warning signs include agitation, confusion, fever, sweating, rapid heart rate, tremor, muscle rigidity, and diarrhoea—seek emergency medical care if suspected. Report persistent or troublesome adverse effects to your healthcare professional; dose changes or alternative therapies may be appropriate.
Avoid MAOIs and allow a 14-day washout. Combining amitriptyline with other serotonergic agents (SSRIs such as fluoxetine, sertraline; SNRIs; tramadol; linezolid; triptans; St John’s wort) can raise serotonin syndrome risk. Many SSRIs and bupropion inhibit CYP2D6, potentially increasing amitriptyline levels and side effects; fluoxetine and paroxetine are notable. If combinations are necessary, clinicians often reduce the TCA dose and monitor closely.
Additive sedation occurs with alcohol, benzodiazepines, opioids, sedating antihistamines, and sleep medicines. Anticholinergic burden increases with drugs such as oxybutynin, benztropine, or first-generation antihistamines, raising risks of constipation, confusion, and urinary retention. Medicines that prolong QT interval (certain antipsychotics, macrolide antibiotics, methadone, and some antiarrhythmics) may compound cardiac risk—consider ECG monitoring and alternatives when possible.
Cimetidine can increase TCA concentrations; dose adjustments may be needed. Carbamazepine can lower TCA levels. Blood pressure medicines may have altered effects due to TCA-induced noradrenaline reuptake blockade. Always give your prescriber and pharmacist a complete list of medicines and supplements so they can proactively check for interactions.
If you take amitriptyline once nightly and miss a dose, take it when remembered unless it is close to your usual wake time; if so, skip the missed dose and resume your regular schedule that evening. Do not double doses. For multiple-daily dosing, take the missed dose when remembered unless it is almost time for the next dose—then skip it. Keeping a consistent schedule helps maintain effectiveness and reduce side effects.
An amitriptyline overdose is a medical emergency. Symptoms can include profound drowsiness, confusion, agitation, seizures, rapid or irregular heartbeat, low blood pressure, widened QRS on ECG, fever, dilated pupils, and pronounced anticholinergic signs (very dry mouth, flushed skin, urinary retention). If overdose is suspected in Australia, call 000 for emergency services or contact the Poisons Information Centre on 13 11 26 immediately. Do not induce vomiting unless advised by medical professionals. Hospital care may include cardiac monitoring, airway support, and IV sodium bicarbonate to treat cardiotoxicity.
Store amitriptyline tablets below 25°C in a dry place away from light and moisture. Keep the medicine in the original child-resistant container and out of reach of children and pets. Do not use after the expiry date. For safe disposal in Australia, return unwanted medicines to your local pharmacy through the Return Unwanted Medicines (RUM) Project; do not flush medicines unless specifically instructed. The Therapeutic Goods Administration (TGA) and your pharmacist can provide disposal guidance.
During pregnancy, amitriptyline may be considered when the expected benefits outweigh potential risks; discuss family planning and treatment goals with your clinician. Late-pregnancy exposure can lead to transient neonatal symptoms (jitteriness, feeding difficulties). During breastfeeding, small amounts pass into milk—monitor infants for excessive sleepiness or poor feeding. In older adults, use the lowest effective dose, monitor for cognitive changes, constipation, urinary retention, falls, and cardiac effects, and regularly review medicines to minimise anticholinergic burden.
Start at night to make use of the sedative effect, and titrate slowly. Manage dry mouth with water, sugar-free gum, or saliva substitutes; constipation with fibre, fluids, and regular activity; and dizziness by rising slowly. Limit alcohol and avoid combining with other sedatives. Consider periodic weight and blood pressure checks. If daytime drowsiness persists, ask about earlier evening dosing or dose reduction. Never stop abruptly—plan a taper with your prescriber.
In Australia, amitriptyline is a Schedule 4 (Prescription Only) medicine. Australian law requires a valid prescription from an authorised prescriber (for example, a GP, psychiatrist, or nurse practitioner) for it to be dispensed. Buying or selling prescription medicines without a prescription is illegal and unsafe. Avoid websites that offer amitriptyline without a prescription—these products may be counterfeit, subpotent, contaminated, or dangerous. For legal, safe access, use Australian-registered pharmacies and consider telehealth with an Australian prescriber, including ePrescriptions sent directly to your chosen pharmacy.
Australian health services can provide structured, lawful care pathways that include assessment, monitoring, and prescriptions when clinically appropriate; however, there is no legitimate program in Australia that supplies amitriptyline without a valid prescription. To reduce costs, ask about PBS-subsidised options, generic brands, concessional co-payments, Safety Net thresholds, and longer dispensing intervals where eligible (for example, 60-day dispensing on selected items). When using online pharmacies, ensure they are Australian-registered: check pharmacy premises registration with your state or territory pharmacy authority (e.g., Victorian Pharmacy Authority, Pharmacy Council of NSW) and confirm pharmacist registration via Ahpra. Prefer services that require a valid Australian prescription and provide pharmacist counselling.
Amitriptyline is a tricyclic antidepressant (TCA) that increases the brain’s levels of serotonin and norepinephrine by blocking their reuptake. It also has antihistamine and anticholinergic effects, which contribute to sedation and some side effects.
Beyond major depressive disorder, clinicians use amitriptyline off-label for neuropathic pain (such as diabetic neuropathy and postherpetic neuralgia), migraine prevention, tension-type headache, fibromyalgia, irritable bowel syndrome–related pain, and chronic insomnia when comorbid with pain or depression.
For mood, it often takes 2–4 weeks to notice improvement, with full effects by 6–8 weeks. For neuropathic pain or migraine prevention, some benefit may appear within 1–2 weeks, with optimal response over 4–6 weeks. Sedation can occur from the first dose.
Common effects include dry mouth, constipation, blurred vision, urinary hesitancy, drowsiness, dizziness, increased appetite, weight gain, sweating, and orthostatic lightheadedness. Many are dose-related and may lessen as your body adjusts.
Seek urgent help for chest pain, irregular heartbeat, fainting, seizures, severe constipation or urinary retention, vision changes (especially eye pain/redness), confusion, fever/rigidity (possible serotonin syndrome), severe rash, or thoughts of suicide. TCAs can prolong QT and are dangerous in overdose.
Dosing is individualized. For depression, total daily doses often range from 75–150 mg (sometimes higher), typically split or taken at night. For pain or migraine prevention, low-dose regimens (10–25 mg nightly) are common, titrated slowly (for example, by 10–25 mg every 1–2 weeks) to effect and tolerability. Always follow your prescriber’s plan.
Yes. Its antihistamine and anticholinergic actions make it sedating, which can help with sleep onset and maintenance, especially when pain contributes to insomnia. Morning grogginess can occur; taking it earlier in the evening may help.
Amitriptyline is not addictive in the classic sense and does not produce a “high.” However, abrupt discontinuation can cause withdrawal-like symptoms (nausea, headache, sleep disturbance, irritability), so tapering is recommended.
Alcohol can amplify drowsiness, dizziness, and judgment impairment and may increase risk of overdose or breathing problems. If you drink, keep it minimal and avoid hazardous activities; many clinicians advise avoiding alcohol altogether.
Do not combine with MAO inhibitors (and allow a 14-day washout). Use caution with SSRIs/SNRIs, tramadol, linezolid, lithium, and St. John’s wort due to serotonin syndrome risk. CYP2D6 inhibitors (such as fluoxetine, paroxetine, bupropion, quinidine) can raise amitriptyline levels. Additive sedation occurs with benzodiazepines, opioids, antihistamines, and alcohol. Other anticholinergics can worsen dryness/constipation. QT-prolonging drugs may increase arrhythmia risk.
Data in pregnancy are limited; risks and benefits should be weighed carefully. Some newborns may experience transient adaptation symptoms if exposed late in pregnancy. In breastfeeding, small amounts enter milk; some infants may show drowsiness or poor feeding. Discuss individualized options with your clinician.
It can increase appetite and weight due to antihistamine and anticholinergic effects and improved sleep. Strategies include mindful eating, regular physical activity, and choosing lower-calorie, high-fiber foods.
Avoid driving or operating machinery until you know how it affects you. Sedation, blurred vision, and slowed reaction time are common early in treatment or after dose increases.
Call emergency services immediately. TCA overdose is a medical emergency due to life-threatening arrhythmias, seizures, and profound hypotension. Do not wait for symptoms.
Work with your prescriber on a gradual taper, often reducing by 10–25% of the dose every 1–2 weeks, slower if withdrawal symptoms occur or if you have been on a high dose or long duration.
Like other antidepressants, amitriptyline carries a boxed warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults, particularly early in treatment or after dose changes. Close monitoring is essential.
Yes. Its anticholinergic effects can precipitate angle-closure glaucoma in susceptible individuals and worsen urinary retention in men with benign prostatic hyperplasia. Eye exam and urology input may be appropriate.
Baseline and periodic ECGs may be advised in those with cardiac risk, electrolyte checks if on diuretics, and review of side effects, mood, suicidality, weight, and blood pressure. Plasma levels are rarely needed but can help in suspected toxicity or nonresponse.
It can be effective but is often less favored due to anticholinergic burden, orthostatic hypotension, and fall risk. Lower starting doses, slow titration, and considering alternatives like nortriptyline or desipramine may improve tolerability.
Nortriptyline is the active metabolite of amitriptyline and tends to be less sedating and less anticholinergic, so it’s often better tolerated, especially in older adults. Amitriptyline may be slightly more sedating and useful when sleep or headache prevention is desired. Both are effective for depression and neuropathic pain.
Both TCAs are effective for depression. Imipramine has robust evidence and is sometimes used for pediatric enuresis, while amitriptyline is commonly chosen for pain and migraine prevention due to sedation. Side-effect profiles are broadly similar; individual response and tolerability guide the choice.
Desipramine is more noradrenergic and generally less sedating and less anticholinergic than amitriptyline. It may suit patients who need fewer anticholinergic effects or have daytime fatigue. Amitriptyline can be preferable when insomnia or headache is prominent.
Both are sedating TCAs. Low-dose doxepin (3–6 mg) is FDA-approved specifically for insomnia maintenance and has fewer anticholinergic effects at those doses. Amitriptyline can aid sleep at low doses and additionally treats pain and migraines, but may cause more dry mouth and constipation.
Clomipramine is the most serotonergic TCA and is particularly effective for obsessive-compulsive disorder, often rivaling SSRIs. It can have more serotonergic and anticholinergic side effects. Amitriptyline is not first-line for OCD but is versatile for depression with comorbid pain or headaches.
Protriptyline is relatively activating and less sedating, sometimes helpful for patients with excessive daytime sleepiness. Amitriptyline is more sedating and better for insomnia or headache prevention. Both have anticholinergic risks; ECG monitoring may be considered.
Trimipramine is highly sedating with strong antihistamine effects and relatively weak reuptake inhibition, sometimes used when insomnia dominates. Amitriptyline offers broader evidence for pain and migraine prophylaxis. Trimipramine may cause less sexual dysfunction but more daytime grogginess.
Maprotiline is a tetracyclic related to TCAs with strong noradrenergic effects; it can be less anticholinergic but carries a higher seizure risk, especially at higher doses. Amitriptyline has more evidence in neuropathic pain and migraine prevention and is more sedating.
Amoxapine has some dopamine receptor antagonism and can cause extrapyramidal symptoms and tardive dyskinesia, which are not typical of amitriptyline. Amitriptyline is preferred when avoiding dopamine blockade; amoxapine may be considered in select treatment-resistant cases.
Both help neuropathic pain at low to moderate doses. Amitriptyline may be slightly more effective for some patients but is more sedating. Nortriptyline often has a better side-effect profile, making it a common choice in older adults or those sensitive to anticholinergics.
Desipramine’s activating profile can improve daytime energy and concentration in some, whereas amitriptyline’s sedation may impair it. For patients struggling with fatigue or cognitive slowing, desipramine or nortriptyline may be better tolerated.
Nortriptyline and desipramine are usually favored over amitriptyline in older adults due to lower anticholinergic load and reduced risk of orthostatic hypotension and falls. If amitriptyline is used, start low and go slow, with close monitoring.
Amitriptyline has the most migraine evidence among TCAs and is widely used at low doses. Doxepin and nortriptyline may help but are less studied. Side effects guide choice: use amitriptyline when sedation is acceptable or helpful; consider nortriptyline if daytime alertness is a priority.
Both can cause sexual dysfunction, but clomipramine’s stronger serotonergic activity may increase risk of delayed orgasm and decreased libido. Amitriptyline’s anticholinergic profile can also contribute, though individual responses vary.
All TCAs can affect cardiac conduction and prolong QT. Imipramine and amitriptyline have similar cardiotoxicity profiles, especially in overdose. Baseline ECG and cautious dosing are prudent in patients with cardiac disease or on QT-prolonging drugs.
Amitriptyline typically causes more anticholinergic effects than low-dose doxepin used for insomnia. At antidepressant doses, both can cause significant dryness and constipation; stool softeners, hydration, and fiber can help, and the less anticholinergic option may be preferred.